| ||
| ||
Orexigen's Diet Drug Springs Back to Life, Independa Gets $1.6M, NuVasive ... Xconomy —After meeting with federal regulators, San Diego's Orexigen Therapeutics (NASDAQ: OREX) said it is restarting work on its experimental diet pill, a combination of naltrexone and bupriopion (Contrave), after declaring in June that it was suspending ... See all stories on this topic » | ||
|
Tip: Use a plus sign (+) to match a term in your query exactly as is. Learn more.
Delete this alert.
Create another alert.
Manage your alerts.
No comments:
Post a Comment